Tyra Biosciences Inc (TYRA)

Currency in USD
27.99
-1.20(-4.11%)
Closed·
28.29+0.30(+1.07%)
·
TYRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.8230.26
52 wk Range
6.4233.99
Key Statistics
Prev. Close
29.19
Open
29.41
Day's Range
27.82-30.26
52 wk Range
6.42-33.99
Volume
481.52K
Average Volume (3m)
641.57K
1-Year Change
112.2062%
Book Value / Share
5.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TYRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.62
Upside
+70.15%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Tyra Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Tyra Biosciences Inc Company Profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Compare TYRA to Peers and Sector

Metrics to compare
TYRA
Peers
Sector
Relationship
P/E Ratio
−13.4x−11.0x−0.5x
PEG Ratio
0.69−0.220.00
Price/Book
5.3x6.6x2.6x
Price / LTM Sales
-102.0x3.3x
Upside (Analyst Target)
78.6%58.3%47.0%
Fair Value Upside
Unlock−15.6%5.9%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 47.62
(+70.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wedbush
Buy53.00+89.35%37.00MaintainFeb 13, 2026
William Blair
Buy---New CoverageFeb 10, 2026
Oppenheimer
Buy50.00+78.64%36.00MaintainFeb 03, 2026
Raymond James
Buy55.00+96.50%35.00MaintainJan 28, 2026
Barclays
Buy59.00+110.79%-New CoverageJan 28, 2026

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.50 / -0.50
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TYRA Income Statement

People Also Watch

67.78
APGE
-2.21%
12.000
ERAS
-2.52%
8.75
UPB
-31.64%
7.26
KYTX
-1.36%
38.09
MBX
+0.24%

FAQ

What Is the Tyra Biosciences (TYRA) Stock Price Today?

The Tyra Biosciences stock price today is 27.99

What Stock Exchange Does Tyra Biosciences Trade On?

Tyra Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Tyra Biosciences?

The stock symbol for Tyra Biosciences is "TYRA."

What Is the Tyra Biosciences Market Cap?

As of today, Tyra Biosciences market cap is 1.49B.

What Is Tyra Biosciences's Earnings Per Share (TTM)?

The Tyra Biosciences EPS (TTM) is -1.88.

When Is the Next Tyra Biosciences Earnings Date?

Tyra Biosciences will release its next earnings report on Mar 25, 2026.

From a Technical Analysis Perspective, Is TYRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Tyra Biosciences Stock Split?

Tyra Biosciences has split 0 times.

How Many Employees Does Tyra Biosciences Have?

Tyra Biosciences has 60 employees.

What is the current trading status of Tyra Biosciences (TYRA)?

As of Feb 16, 2026, Tyra Biosciences (TYRA) is trading at a price of 27.99, with a previous close of 29.19. The stock has fluctuated within a day range of 27.82 to 30.26, while its 52-week range spans from 6.42 to 33.99.

What Is Tyra Biosciences (TYRA) Price Target According to Analysts?

The average 12-month price target for Tyra Biosciences is USD47.62, with a high estimate of USD59.62 and a low estimate of USD30. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +70.15% Upside potential.

What Is the TYRA After Hours Price?

TYRA's last after hours stock price is 28.29, the stock has decreased by 0.30, or 1.07%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.